Your browser doesn't support javascript.
loading
Identification of patterns of factors preceding severe or life-threatening asthma exacerbations in a nationwide study.
Tanaka, H; Nakatani, E; Fukutomi, Y; Sekiya, K; Kaneda, H; Iikura, M; Yoshida, M; Takahashi, K; Tomii, K; Nishikawa, M; Kaneko, N; Sugino, Y; Shinkai, M; Ueda, T; Tanikawa, Y; Shirai, T; Hirabayashi, M; Aoki, T; Kato, T; Iizuka, K; Fujii, M; Taniguchi, M.
Afiliação
  • Tanaka H; NPO Sapporo Cough Asthma, and Allergy Center, Sapporo, Japan.
  • Nakatani E; Formerly at the Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan.
  • Fukutomi Y; Translational Research Informatics Center, Foundation for Biomedical Research and Innovation, Kobe, Japan.
  • Sekiya K; Department of Biostatistics and Data Science, Osaka University Graduate School of Medicine, Suita, Japan.
  • Kaneda H; Clinical Research Center for Allergology and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan.
  • Iikura M; Clinical Research Center for Allergology and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan.
  • Yoshida M; Department of Biostatistics and Data Science, Osaka University Graduate School of Medicine, Suita, Japan.
  • Takahashi K; Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan.
  • Tomii K; Division of Respiratory Medicine, National Hospital Organization Fukuoka Hospital, Fukuoka, Japan.
  • Nishikawa M; Department of Respiratory Diseases and Chest Surgery, Otsu Red Cross Hospital, Otsu, Japan.
  • Kaneko N; Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Sugino Y; Department of Respiratory Medicine, Fujisawa City Hospital, Fujisawa, Japan.
  • Shinkai M; Department of Pulmonary Medicine, Kameda Medical Center, Kamogawa, Japan.
  • Ueda T; Department of Respiratory Medicine, Toyota Memorial Hospital, Toyota, Japan.
  • Tanikawa Y; Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, Japan.
  • Shirai T; The Department of Respiratory Medicine, Saiseikai Nakatsu Hospital, Osaka, Japan.
  • Hirabayashi M; Department of Respiratory Medicine and Clinical Immunology, Toyota Kosei Hospital, Toyota, Japan.
  • Aoki T; Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan.
  • Kato T; Department of Respiratory Diseases, Amagasaki General Medical Center, Amagasaki, Japan.
  • Iizuka K; Department of Internal Medicine, Respiratory Division, Tokai University School of Medicine, Isehara, Japan.
  • Fujii M; Department of Respiratory Medicine and Allergology, Kariya Toyota General Hospital, Kariya, Japan.
  • Taniguchi M; Internal Medicine, Public Tomioka General Hospital, Tomioka, Japan.
Allergy ; 73(5): 1110-1118, 2018 05.
Article em En | MEDLINE | ID: mdl-29197099
ABSTRACT

BACKGROUND:

Reducing near-fatal asthma exacerbations is a critical problem in asthma management.

OBJECTIVES:

To determine patterns of factors preceding asthma exacerbations in a real-world setting.

METHODS:

In a nationwide prospective study of 190 patients who had experienced near-fatal asthma exacerbation, cluster analysis was performed using asthma symptoms over the 2-week period before admission.

RESULTS:

Three distinct clusters of symptoms were defined employing the self-reporting of a visual analogue scale. Cluster A (42.1%) rapid worsening within 7.4 hours from moderate attack to admission, young to middle-aged patients with low Body mass index and tendency to depression who had stopped anti-asthma medications, smoked, and hypersensitive to environmental triggers and furred pets. Cluster B (40.0%) fairly rapid worsening within 48 hours, mostly middle-aged and older, relatively good inhaled corticosteroid (ICS) or ICS/long-acting beta-agonist (LABA) compliance, and low perception of dyspnea. Cluster C (17.9%) slow worsening over 10 days before admission, high perception of dyspnea, smokers, and chronic daily mild-moderate symptoms. There were no differences in overuse of short-acting beta-agonists, baseline asthma severity, or outcomes after admission for patients in these 3 clusters.

CONCLUSION:

To reduce severe or life-threatening asthma exacerbation, personalized asthma management plans should be considered for each cluster. Improvement of ICS and ICS/LABA compliance and cessation of smoking are important in cluster A. To compensate for low perception of dyspnea, asthma monitoring of peak expiratory flow rate and/or exhaled nitric oxide would be useful for patients in cluster B. Avoidance of environmental triggers, increase usual therapy, or new anti-type 2 response-targeted therapies should be considered for cluster C.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Ano de publicação: 2018 Tipo de documento: Article